Table of Content
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF GLOBAL TRANSTHYRETIN AMYLOID CARDIOMYOPATHY TREATMENT MARKET
1.4 CURRENCY AND PRICING
1.5 LIMITATION
1.6 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 KEY TAKEAWAYS
2.2 ARRIVING AT THE GLOBAL TRANSTHYRETIN AMYLOID CARDIOMYOPATHY TREATMENT MARKET SIZE
2.2.1 VENDOR POSITIONING GRID
2.2.2 TECHNOLOGY LIFE LINE CURVE
2.2.3 TRIPOD DATA VALIDATION MODEL
2.2.4 MARKET GUIDE
2.2.5 MULTIVARIATE MODELLING
2.2.6 TOP TO BOTTOM ANALYSIS
2.2.7 CHALLENGE MATRIX
2.2.8 APPLICATION COVERAGE GRID
2.2.9 STANDARDS OF MEASUREMENT
2.2.10 VENDOR SHARE ANALYSIS
2.2.11 EPIDEMIOLOGY MODELING
2.2.12 DATA POINTS FROM KEY PRIMARY INTERVIEWS
2.2.13 DATA POINTS FROM KEY SECONDARY DATABASES
2.3 GLOBAL TRANSTHYRETIN AMYLOID CARDIOMYOPATHY TREATMENT MARKET: RESEARCH SNAPSHOT
2.4 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PORTER'S 5 FORCES
4.2 PESTEL ANALYSIS
5 EPIDEMIOLOGY
5.1 INCIDENCE OF ALL BY GENDER
5.2 TREATMENT RATE
5.3 MORTALITY RATE
5.4 DRUG ADHERENCE AND THERAPY SWITCH MODEL
5.5 PATEINT TREATMENT SUCCESS RATES
6 INDUSTRY INSIGHTS
6.1 PATENT ANALYSIS
6.2 DRUG TREATMENT RATE BY MATURED MARKETS
6.3 DEMOGRAPHIC TRENDS: IMPACTS ON ALL INCIDENCE RATES
6.4 PATIENT FLOW DIAGRAM
6.5 KEY PRICING STRATEGIES
6.6 KEY PATIENT ENROLLMENT STRATEGIES
6.7 INTERVIEWS WITH CARDIOLOGIST
6.8 OTHER KOL SNAPSHOTS
7 REGULATORY SCENARIO
8 PIPELINE ANALYSIS
8.1 CLINICAL TRIALS AND PHASE ANALYSIS
8.2 DRUG THERAPY PIPELINE
8.2.1 PRX-004
8.2.2 AG10
8.2.3 OTHERS
8.3 PHASE III CANDIDATES
8.4 PHASE II CANDIDATES
8.5 PHASE I CANDIDATES
8.6 OTHERS (PRE-CLINICAL AND RESEARCH)
9 MARKET OVERVIEW
9.1 DRIVERS
9.2 RESTRAINS
9.3 OPPURTUNITY
9.4 CHALLENGES
10 GLOBAL TRANSTHYRETIN AMYLOID CARDIOMYOPATHY TREATMENT MARKET, BY TYPE
10.1 OVERVIEW
10.2 FAMILIAL AMYLOIDOSIS (ATTRM)
10.2.1 ONPATTRO
10.2.2 TEGSEDI
10.2.3 VYNDAMAX
10.3 WILD-TYPE AMYLOIDOSIS (ATTRWT)
10.3.1 VYNDAQEL
11 GLOBAL TRANSTHYRETIN AMYLOID CARDIOMYOPATHY TREATMENT MARKET, BY TREATMENT
12 (NOTE: MARKET VALUE, VOLUME AND ASP ANALYSIS WOULD BE PROVIDED FOR ALL SEGMENTS AND SUB-SEGMENTS)
12.1 OVERVIEW
12.2 MEDICATION
12.2.1 ATTR SILENCERS
12.2.1.1. PATISIRAN
12.2.1.2. INOTERSEN
12.2.2 ATTR STABILIZERS
12.2.2.1. TAFAMIDIS
12.2.2.2. AG10
12.2.3 NONSTEROIDAL ANTI-INFLAMMATORY DRUG (NSAID)
12.2.3.1. DIFLUNSIAL
12.2.3.2. OTHERS
12.2.4 FIBRIL DISRUPTORS
12.2.4.1. DOXYCYCLINE
12.2.4.2. TAUROURSODEOXYCHOLIC ACID
12.2.5 ANTICOAGULANTS
12.2.5.1. INJECTABLE
12.2.5.1.1. WARFARIN
12.2.5.1.2. OTHERS
12.2.5.2. ORAL
12.2.5.2.1. APIXABAN
12.2.5.2.2. RIVAROXABAN
12.2.6 ANTIARRHYTHMICS
12.2.6.1. AMIODARONE
12.2.6.2. OTHERS
12.2.7 LOOP DIURETICS
12.2.7.1. TORSEMIDE
12.2.7.2. BUMETANIDE
12.3 TRANSPLANTATION
12.3.1 LIVER TRANSPLANTATION
12.3.1.1. MARKET VALUE (USD)
12.3.1.2. MARKET VOLUME (UNIT)
12.3.1.3. ASP (USD)
12.3.2 HEART TRANSPLANTATION
12.3.2.1. MARKET VALUE (USD)
12.3.2.2. MARKET VOLUME (UNIT)
12.3.2.3. ASP (USD)
12.4 PACEMAKERS
12.4.1 MARKET VALUE (USD)
12.4.2 MARKET VOLUME (UNIT)
12.4.3 ASP (USD)
13 GLOBAL TRANSTHYRETIN AMYLOID CARDIOMYOPATHY TREATMENT MARKET, BY PATIENT TYPE
13.1 OVERVIEW
13.2 CHILD
13.2.1 MALE
13.2.2 FEMALE
13.3 ADULT
13.3.1 MALE
13.3.2 FEMALE
13.4 GERIATRIC
13.4.1 MALE
13.4.2 FEMALE
14 GLOBAL TRANSTHYRETIN AMYLOID CARDIOMYOPATHY TREATMENT MARKET, BY DOSAGE FORM
14.1 OVERVIEW
14.2 ORAL
14.2.1 SOLID
14.2.1.1. TABLETS
14.2.1.2. CAPSULES
14.2.1.3. OTHERS
14.2.2 LIQUID
14.2.2.1. SOLUTIONS
14.2.2.2. SYRUPS
14.2.2.3. OTHERS
14.3 PARENTERAL
14.3.1 INFUSION
14.3.2 INTRAVENOUS
14.3.3 OTHERS
15 GLOBAL TRANSTHYRETIN AMYLOID CARDIOMYOPATHY TREATMENT MARKET, BY END USER
15.1 OVERVIEW
15.2 HOSPITAL
15.3 CLINICS
15.4 HOME HEALTHCARE
15.5 SPECIALITY CENTER
15.6 AMBULTORY CENTERS
15.7 OTHERS
16 GLOBAL TRANSTHYRETIN AMYLOID CARDIOMYOPATHY TREATMENT MARKET, BY DISTRIBUTION CHANNEL
16.1 OVERVIEW
16.2 HOSPITAL PHARMACY
16.3 ONLINE PHARMACY
16.4 RETAIL PHARMACY
16.5 OTHERS
17 GLOBAL TRANSTHYRETIN AMYLOID CARDIOMYOPATHY TREATMENT MARKET, BY GEOGRAPHY
17.1 GLOBAL TRANSTHYRETIN AMYLOID CARDIOMYOPATHY TREATMENT MARKET, (ALL SEGMENTATION PROVIDED ABOVE IS REPRESENTED IN THIS CHAPTER BY COUNTRY)
17.2 NORTH AMERICA
17.2.1 U.S.
17.2.1.1. U.S. TRANSTHYRETIN AMYLOID CARDIOMYOPATHY TREATMENT MARKET, BY TYPE
17.2.1.2. U.S. TRANSTHYRETIN AMYLOID CARDIOMYOPATHY TREATMENT MARKET, BY TREATMENT
17.2.1.3. U.S. TRANSTHYRETIN AMYLOID CARDIOMYOPATHY TREATMENT MARKET, BY PATIENT TYPE
17.2.1.4. U.S. TRANSTHYRETIN AMYLOID CARDIOMYOPATHY TREATMENT MARKET, BY DOSAGE FORM
17.2.1.5. U.S. TRANSTHYRETIN AMYLOID CARDIOMYOPATHY TREATMENT MARKET, BY END USER
17.2.1.6. U.S. TRANSTHYRETIN AMYLOID CARDIOMYOPATHY TREATMENT MARKET, BY DISTRIBUTION CHANNEL
17.2.2 CANADA
17.2.3 MEXICO
17.3 EUROPE
17.3.1 GERMANY
17.3.2 FRANCE
17.3.3 U.K.
17.3.4 HUNGARY
17.3.5 LITHUANIA
17.3.6 AUSTRIA
17.3.7 IRELAND
17.3.8 NORWAY
17.3.9 POLAND
17.3.10 ITALY
17.3.11 SPAIN
17.3.12 RUSSIA
17.3.13 TURKEY
17.3.14 NETHERLANDS
17.3.15 SWITZERLAND
17.3.16 REST OF EUROPE
17.4 ASIA-PACIFIC
17.4.1 JAPAN
17.4.2 CHINA
17.4.3 SOUTH KOREA
17.4.4 INDIA
17.4.5 AUSTRALIA
17.4.6 SINGAPORE
17.4.7 THAILAND
17.4.8 MALAYSIA
17.4.9 INDONESIA
17.4.10 PHILIPPINES
17.4.11 VIETNAM
17.4.12 REST OF ASIA-PACIFIC
17.5 SOUTH AMERICA
17.5.1 BRAZIL
17.5.2 ARGENTINA
17.5.3 PERU
17.5.4 REST OF SOUTH AMERICA
17.6 MIDDLE EAST AND AFRICA
17.6.1 SOUTH AFRICA
17.6.2 SAUDI ARABIA
17.6.3 UAE
17.6.4 EGYPT
17.6.5 KUWAIT
17.6.6 ISRAEL
17.6.7 REST OF MIDDLE EAST AND AFRICA
17.7 KEY PRIMARY INSIGHTS: BY MAJOR COUNTRIES
18 GLOBAL TRANSTHYRETIN AMYLOID CARDIOMYOPATHY TREATMENT MARKET, SWOT AND DBMR ANALYSIS
19 GLOBAL TRANSTHYRETIN AMYLOID CARDIOMYOPATHY TREATMENT MARKET, COMPANY LANDSCAPE
19.1 COMPANY SHARE ANALYSIS: GLOBAL
19.2 COMPANY SHARE ANALYSIS: NORTH AMERICA
19.3 COMPANY SHARE ANALYSIS: EUROPE
19.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC
19.5 MERGERS & ACQUISITIONS
19.6 NEW PRODUCT DEVELOPMENT & APPROVALS
19.7 EXPANSIONS
19.8 REGULATORY CHANGES
19.9 PARTNERSHIP AND OTHER STRATEGIC DEVELOPMENTS
20 GLOBAL TRANSTHYRETIN AMYLOID CARDIOMYOPATHY TREATMENT MARKET, COMPANY PROFILE
20.1 ALNYLAM PHARMACEUTICALS, INC
20.1.1 COMPANY OVERVIEW
20.1.2 REVENUE ANALYSIS
20.1.3 GEOGRAPHIC PRESENCE
20.1.4 PRODUCT PORTFOLIO
20.1.5 RECENT DEVELOPMENTS
20.2 AKCEA THERAPEUTICS
20.2.1 COMPANY OVERVIEW
20.2.2 REVENUE ANALYSIS
20.2.3 GEOGRAPHIC PRESENCE
20.2.4 PRODUCT PORTFOLIO
20.2.5 RECENT DEVELOPMENTS
20.3 PFIZER INC.
20.3.1 COMPANY OVERVIEW
20.3.2 REVENUE ANALYSIS
20.3.3 GEOGRAPHIC PRESENCE
20.3.4 PRODUCT PORTFOLIO
20.3.5 RECENT DEVELOPMENTS
20.4 ARTI INDUSTRIES LTD
20.4.1 COMPANY OVERVIEW
20.4.2 REVENUE ANALYSIS
20.4.3 GEOGRAPHIC PRESENCE
20.4.4 PRODUCT PORTFOLIO
20.4.5 RECENT DEVELOPMENTS
20.5 ENOMARK
20.5.1 COMPANY OVERVIEW
20.5.2 REVENUE ANALYSIS
20.5.3 GEOGRAPHIC PRESENCE
20.5.4 PRODUCT PORTFOLIO
20.5.5 RECENT DEVELOPMENTS
20.6 MAYNE PHARMA
20.6.1 COMPANY OVERVIEW
20.6.2 REVENUE ANALYSIS
20.6.3 GEOGRAPHIC PRESENCE
20.6.4 PRODUCT PORTFOLIO
20.6.5 RECENT DEVELOPMENTS
20.7 FISHER SCIENTIFIC
20.7.1 COMPANY OVERVIEW
20.7.2 REVENUE ANALYSIS
20.7.3 GEOGRAPHIC PRESENCE
20.7.4 PRODUCT PORTFOLIO
20.7.5 RECENT DEVELOPMENTS
20.8 AMIRALL
20.8.1 COMPANY OVERVIEW
20.8.2 REVENUE ANALYSIS
20.8.3 GEOGRAPHIC PRESENCE
20.8.4 PRODUCT PORTFOLIO
20.8.5 RECENT DEVELOPMENTS
20.9 TEVA PHARMACEUTICAL USA, INC
20.9.1 COMPANY OVERVIEW
20.9.2 REVENUE ANALYSIS
20.9.3 GEOGRAPHIC PRESENCE
20.9.4 PRODUCT PORTFOLIO
20.9.5 RECENT DEVELOPMENTS
20.1 LUPIN PHARMACEUTICAL, INC
20.10.1 COMPANY OVERVIEW
20.10.2 REVENUE ANALYSIS
20.10.3 GEOGRAPHIC PRESENCE
20.10.4 PRODUCT PORTFOLIO
20.10.5 RECENT DEVELOPMENTS
20.11 UPSHER-SMITH LABORATORIES, LLC
20.11.1 COMPANY OVERVIEW
20.11.2 REVENUE ANALYSIS
20.11.3 GEOGRAPHIC PRESENCE
20.11.4 PRODUCT PORTFOLIO
20.11.5 RECENT DEVELOPMENTS
20.12 BRISTOL MEYERS SQUIBB COMPANY
20.12.1 COMPANY OVERVIEW
20.12.2 REVENUE ANALYSIS
20.12.3 GEOGRAPHIC PRESENCE
20.12.4 PRODUCT PORTFOLIO
20.12.5 RECENT DEVELOPMENTS
20.13 DR REDDY’S LABORATORIES LTD
20.13.1 COMPANY OVERVIEW
20.13.2 REVENUE ANALYSIS
20.13.3 GEOGRAPHIC PRESENCE
20.13.4 PRODUCT PORTFOLIO
20.13.5 RECENT DEVELOPMENTS
20.14 BAYER AG
20.14.1 COMPANY OVERVIEW
20.14.2 REVENUE ANALYSIS
20.14.3 GEOGRAPHIC PRESENCE
20.14.4 PRODUCT PORTFOLIO
20.14.5 RECENT DEVELOPMENTS
20.15 CAMBER PHARMACEUTICALS
20.15.1 COMPANY OVERVIEW
20.15.2 REVENUE ANALYSIS
20.15.3 GEOGRAPHIC PRESENCE
20.15.4 PRODUCT PORTFOLIO
20.15.5 RECENT DEVELOPMENTS
20.16 SARFEZ
20.16.1 COMPANY OVERVIEW
20.16.2 REVENUE ANALYSIS
20.16.3 GEOGRAPHIC PRESENCE
20.16.4 PRODUCT PORTFOLIO
20.16.5 RECENT DEVELOPMENTS
20.17 MEDTRONIC
20.17.1 COMPANY OVERVIEW
20.17.2 REVENUE ANALYSIS
20.17.3 GEOGRAPHIC PRESENCE
20.17.4 PRODUCT PORTFOLIO
20.17.5 RECENT DEVELOPMENTS
20.18 ABBOTT
20.18.1 COMPANY OVERVIEW
20.18.2 REVENUE ANALYSIS
20.18.3 GEOGRAPHIC PRESENCE
20.18.4 PRODUCT PORTFOLIO
20.18.5 RECENT DEVELOPMENTS
20.19 BOSTON SCIENTIC CORPORATION
20.19.1 COMPANY OVERVIEW
20.19.2 REVENUE ANALYSIS
20.19.3 GEOGRAPHIC PRESENCE
20.19.4 PRODUCT PORTFOLIO
20.19.5 RECENT DEVELOPMENTS
20.2 OSCOR INC
20.20.1 COMPANY OVERVIEW
20.20.2 REVENUE ANALYSIS
20.20.3 GEOGRAPHIC PRESENCE
20.20.4 PRODUCT PORTFOLIO
20.20.5 RECENT DEVELOPMENTS
20.21 BIOTRINIK
20.21.1 COMPANY OVERVIEW
20.21.2 REVENUE ANALYSIS
20.21.3 GEOGRAPHIC PRESENCE
20.21.4 PRODUCT PORTFOLIO
20.21.5 RECENT DEVELOPMENTS
20.22 MICROPORT SCIENTIFIC CORPORATION
20.22.1 COMPANY OVERVIEW
20.22.2 REVENUE ANALYSIS
20.22.3 GEOGRAPHIC PRESENCE
20.22.4 PRODUCT PORTFOLIO
20.22.5 RECENT DEVELOPMENTS
20.23 OSCOR INC
20.23.1 COMPANY OVERVIEW
20.23.2 REVENUE ANALYSIS
20.23.3 GEOGRAPHIC PRESENCE
20.23.4 PRODUCT PORTFOLIO
20.23.5 RECENT DEVELOPMENTS
20.24 PACETRONIX
20.24.1 COMPANY OVERVIEW
20.24.2 PRODUCT PORTFOLIO
20.24.3 REVENUE ANALYSIS
20.24.4 GEOGRAPHIC PRESENCE
20.24.5 PRODUCT PORTFOLIO
20.25 MEDICO S.R.L
20.25.1 COMPANY OVERVIEW
20.25.2 PRODUCT PORTFOLIO
20.25.3 REVENUE ANALYSIS
20.25.4 GEOGRAPHIC PRESENCE
20.25.5 PRODUCT PORTFOLIO
20.26 SUN PHARMACEUTICAL PVT LTD
20.26.1 COMPANY OVERVIEW
20.26.2 PRODUCT PORTFOLIO
20.26.3 REVENUE ANALYSIS
20.26.4 GEOGRAPHIC PRESENCE
20.26.5 PRODUCT PORTFOLIO
20.27 LEPU MEDICAL TECHNOLOGY
20.27.1 COMPANY OVERVIEW
20.27.2 PRODUCT PORTFOLIO
20.27.3 REVENUE ANALYSIS
20.27.4 GEOGRAPHIC PRESENCE
20.27.5 PRODUCT PORTFOLIO
20.28 LIVANOVA PLC
20.28.1 COMPANY OVERVIEW
20.28.2 PRODUCT PORTFOLIO
20.28.3 REVENUE ANALYSIS
20.28.4 GEOGRAPHIC PRESENCE
20.28.5 PRODUCT PORTFOLIO
20.29 MEDICO S.R.L
20.29.1 COMPANY OVERVIEW
20.29.2 PRODUCT PORTFOLIO
20.29.3 REVENUE ANALYSIS
20.29.4 GEOGRAPHIC PRESENCE
20.29.5 PRODUCT PORTFOLIO
20.3 SUN PHARMACEUTICALS PVT LTD
20.30.1 COMPANY OVERVIEW
20.30.2 PRODUCT PORTFOLIO
20.30.3 REVENUE ANALYSIS
20.30.4 GEOGRAPHIC PRESENCE
20.30.5 PRODUCT PORTFOLIO
NOTE: THE COMPANIES PROFILED IS NOT EXHAUSTIVE LIST AND IS AS PER OUR PREVIOUS CLIENT REQUIREMENT. WE PROFILE MORE THAN 100 COMPANIES IN OUR STUDY AND HENCE THE LIST OF COMPANIES CAN BE MODIFIED OR REPLACED ON REQUEST
21 RELATED REPORTS
22 CONCLUSION
23 QUESTIONNAIRE
24 ABOUT DATA BRIDGE MARKET RESEARCH
